HER2 Positive Gastric Cancer Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

HER2 Positive Gastric Cancer Epidemiology Forecast Report Coverage

Expert Market Research's “HER2 Positive Gastric Cancer Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of HER2 positive gastric cancer. It projects the future incidence and prevalence rates of HER2 positive gastric cancer cases across various populations. The study covers age, gender, and type as major determinants of the HER2 positive gastric cancer population. The report highlights patterns in the prevalence of HER2 positive gastric cancer over time and projects future trends based on multiple variables.

HER2 Positive Gastric Cancer Understanding: Disease Overview

HER2-positive gastric cancer is a subtype of stomach cancer that occurs when malignant cells in the gastric lining overexpress the human epidermal growth factor receptor 2 (HER2), a protein involved in cell growth and division. This overexpression leads to faster tumor growth and more aggressive disease behavior. The condition is commonly associated with risk factors such as chronic Helicobacter pylori infection, smoking, high-salt diets, genetic predisposition, and advanced age. If HER2-positive gastric cancer is not diagnosed at an early stage, it can spread to nearby lymph nodes and distant organs, making timely detection and targeted treatment essential.

HER2 Positive Gastric Cancer Epidemiology Perspective

The HER2 positive gastric cancer epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for HER2 positive gastric cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for HER2 positive gastric cancer and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the study “HER2 testing in gastric cancer: An update”, HER2 overexpression or ERBB2 amplification is observed in approximately 10–20% of gastric and gastroesophageal junction (GEJ) adenocarcinomas, with reported prevalence ranging from 7% to 34% and a commonly cited average of ~17–18% in advanced-stage disease.
• An advanced gastric cancer cohort reported a mean age at diagnosis of 61.8 years, with HER2-positive patients showing a similar age distribution to HER2-negative patients, indicating that the disease predominantly affects individuals in their 60s and older, though cases are also observed in younger adults.
• Approximately 70% of advanced gastric cancer patients were male, and HER2-positive tumors are more frequently identified in men, a trend attributed to the higher prevalence of intestinal-type and proximal/GEJ gastric cancers among male patients.
• A Journal of the National Cancer Institute genomic analysis reported ERBB2 (HER2) amplification rates of 13.9% in Hispanic patients, 11.0% in non-Hispanic Black patients, 9.8% in non-Hispanic White patients, and 8.1% in non-Hispanic Asian patients, indicating the highest HER2-positive proportion among Hispanic patients.

Read more about this report - Request a Free Sample

Country-wise HER2 Positive Gastric Cancer Epidemiology

The HER2 positive gastric cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of HER2-positive gastric cancer in the United States varies by age, tumor subtype, and underlying risk factors such as Helicobacter pylori infection, dietary patterns, and molecular characteristics of the tumor. According to the StatPearls “Gastric Cancer” chapter published by the U.S. National Library of Medicine, gastric cancer in the United States represents a smaller but clinically significant cancer burden, with HER2 overexpression or ERBB2 amplification identified in approximately 10–20% of gastric and gastroesophageal junction adenocarcinomas.

HER2 positivity is most strongly associated with the intestinal histologic subtype, which is more common in older adults and contributes disproportionately to the prevalence of HER2-positive disease. Epidemiological data indicate that gastric cancer is typically diagnosed in individuals aged 60 years and older, and HER2-positive cases follow a similar age distribution, while occurrence in children and young adults remains rare in the U.S. population. Advances in biomarker testing and targeted therapy have increased recognition of this subtype, making HER2-positive gastric cancer an important molecularly defined segment within the overall U.S. gastric cancer prevalence.

HER2 Positive Gastric Cancer: Treatment Overview

The primary goals of HER2-positive gastric cancer treatment are to eliminate malignant cells, control disease progression, and improve overall survival, with therapeutic decisions guided by the stage and extent of the disease. In early-stage cases, surgical resection of the tumor is the main treatment approach, often combined with perioperative chemotherapy to reduce the risk of recurrence. For advanced or metastatic disease, systemic chemotherapy remains a cornerstone of treatment, while HER2-targeted therapies specifically inhibit HER2-driven tumor growth. In selected patients, immunotherapy may be used to enhance the body’s immune response against cancer cells. Radiation therapy can also be applied in certain settings to manage local disease or relieve symptoms.

Key Questions Answered

• What are the key findings of HER2 positive gastric cancer epidemiology in the 8 major markets?
• What will be the total number of patients with HER2 positive gastric cancer across the 8 major markets during the forecast period?
• What was the country-wise HER2 positive gastric cancer epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of HER2 positive gastric cancer patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of HER2 positive gastric cancer during the forecast period of 2026-2035?
• What are the currently available treatments for HER2 positive gastric cancer?
• What are the disease risks, signs, symptoms, and unmet needs of HER2 positive gastric cancer?

Scope of the HER2 Positive Gastric Cancer Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of HER2 positive gastric cancer based on several factors.
• HER2 positive gastric cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The HER2 positive gastric cancer report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Gastric Cancer Market

Gastric Cancer Drug Pipeline Analysis Report